Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.300
+0.010 (0.44%)
At close: Mar 6, 2026, 4:00 PM EST
2.290
-0.010 (-0.43%)
After-hours: Mar 6, 2026, 7:06 PM EST
Spero Therapeutics Employees
Spero Therapeutics had 32 employees as of December 31, 2024. The number of employees decreased by 14 or -30.43% compared to the previous year.
Employees
32
Change (1Y)
-14
Growth (1Y)
-30.43%
Revenue / Employee
$1,267,156
Profits / Employee
-$1,369,875
Market Cap
129.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Adagene | 138 |
| Inovio Pharmaceuticals | 134 |
| Connect Biopharma Holdings | 62 |
| Cardiff Oncology | 31 |
| Black Diamond Therapeutics | 24 |
| Genelux | 24 |
SPRO News
- 24 days ago - Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy - Seeking Alpha
- 2 months ago - Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - GlobeNewsWire
- 3 months ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 months ago - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - GlobeNewsWire
- 4 months ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 5 months ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire
- 7 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha